Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03690986 · ClinicalTrials.gov registry record · Phase 1

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

A Phase 1 study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Emory University.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT03690986 is a Phase 1 study of Squamous Cell Carcinoma of the Head and Neck that is actively recruiting participants, run by Emory University. The registered enrollment target is 50 participants, below the 144-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03690986, a Phase 1 study of Squamous Cell Carcinoma of the Head and Neck, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Squamous Cell Carcinoma of the Head and Neck

Interventions

  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Ipilimumab
  • BIOLOGICAL VX15/2503

Study Locations (1)

Georgia

  • Emory University Hospital Midtown - Atlanta

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-11-01
Est. Completion 2027-11-30
Phase Phase 1

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03690986

The ClinicalTrials.gov registry entry for NCT03690986 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (65% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT03690986 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT03690986 about?

NCT03690986 is a clinical study titled "VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer". This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, ma...

What is the current status of trial NCT03690986?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-11-01. Estimated completion is 2027-11-30.

What conditions does trial NCT03690986 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Head and Neck.

What interventions are being tested in trial NCT03690986?

The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), VX15/2503 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03690986?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03690986 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma of the Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma of the Head and Neck

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.